It has been about a month since the last earnings report for Amedisys (AMED) . Shares have added about 1.3% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Amedisys due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns o ...

Amedisys’ (AMED) continuously improving clinical quality for patients, demonstrated through high Quality of Patient Care and Patient Satisfaction star ratings, is poised to drive growth in the upcoming quarters. The company’s valuable partnership and acquisition are expected to generate significant synergies. However, a dull macroeconomic scenario and fierce competitive pressure may restrict Amedisys’ growth potential.In the past year, this Zacks Rank #3 (Hold) company’s shares have risen 0.4% compared with ...

Amedisys, Inc. (AMED) reported fourth-quarter 2024 adjusted earnings per share (EPS) of 96 cents, which rose 2.1% year over year. However, the metric missed the Zacks Consensus Estimate by 8.6%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The quarter’s adjustments include certain merger-related expenses and other (income)/expenses, net.GAAP loss was 62 cents per share against EPS of 59 cents in the corresponding period of 2023.Full-year 2024 adjusted EPS was $4.32, up 0.5% year ove ...

Company Overview - Amedisys operates three segments: home health, hospice, and high acuity care, with approximately 19,000 employees across 519 care centers in 38 states[18]. - The home health segment includes 347 care centers and performed over 10.7 million visits for more than 499,000 patients annually[18][22]. - The high acuity care segment was established through the acquisition of Contessa Health on August 1, 2021, enhancing Amedisys's capabilities in delivering inpatient-level care at home[28]. - The company divested its personal care business on March 31, 2023, streamlining its focus on core healthcare services[31]. - Amedisys has approximately $1.2 billion in goodwill as of December 31, 2024, with additional acquisitions likely to increase this amount[186]. - The company employs around 19,000 employees across various segments, including 11,800 in home health and 6,100 in hospice[183]. Financial Performance - Medicare accounts for approximately 70% to 74% of Amedisys's net service revenue over the last three years, highlighting the company's reliance on government payors[19]. - Medicare accounted for 70%, 73%, and 74% of the company's consolidated net service revenue during 2024, 2023, and 2022, respectively[137]. - The 2025 Home Health Final Rule is expected to result in a 0.5% increase in payments to home health providers, driven by a 2.7% payment update offset by adjustments totaling -2.2%[47]. - CMS estimates a 2.9% increase in hospice payments for fiscal year 2025, with the aggregate cap amount raised to $34,465[52]. - The total temporary adjustment calculated for CY 2020 through CY 2023 is $4.5 billion, with future proposals to convert this amount into a factor applied to base payment rates[47]. - The company anticipates financial benefits from acquisitions, contingent on improving clinical performance and controlling costs[197]. Regulatory Compliance - Compliance with Medicare requirements is monitored through established processes and controls over coding, billing, and patient recertifications[62]. - The company is subject to various audits and compliance reviews by Medicare, which can result in claim adjustments or overpayment determinations[48]. - Compliance with Medicare regulations is essential for participation in the Medicare program, which includes conditions of participation and payment standards[72]. - The company is subject to various federal and state anti-fraud and abuse laws, including the federal Anti-Kickback Statute and the Stark Law, which impose significant penalties for violations[78][81]. - The company must comply with HIPAA regulations, which impose standards for the use and disclosure of health information, with penalties for violations ranging from $141 to a maximum of $2.134 million[93]. - The Improving Medicare Post-Acute Care Transformation Act (IMPACT Act) requires standardized patient assessment data reporting, with penalties for non-compliance resulting in a 2% reduction in market basket prices[98]. Merger and Acquisition Activities - Amedisys entered into a merger agreement with UnitedHealth Group on June 26, 2023, which will result in Amedisys becoming a wholly owned subsidiary[34]. - The proposed Merger with UnitedHealth Group is subject to various closing conditions, including government approvals, which may not be satisfied by the end of the Waiver Period[122]. - Amedisys has incurred significant costs related to the Merger, including potential termination fees of $125 million under certain circumstances[128]. - The ongoing DOJ Action against the Merger creates uncertainty regarding its completion timeline and conditions[124]. - If the Merger is not completed, Amedisys will remain a public company and continue to face risks that could adversely affect its business and stock price[127]. - The Merger Agreement includes restrictions on Amedisys's business activities, potentially limiting strategic opportunities during the pending period[128]. Quality of Care - Amedisys's Quality of Patient Care star average is 4.18, with 88% of care centers rated at 4+ stars, indicating a strong commitment to clinical quality[24]. - Amedisys's hospice outreach strategy has increased its patient population to better reflect community health needs, focusing on conditions like heart disease and dementia[27]. - Quality patient care is crucial for generating referrals; failure to meet quality metrics could adversely impact the company's business[161]. - The company must maintain relationships with existing patient referral sources, as their loss could materially affect financial performance[164]. Operational Risks - The company faces competition from local, publicly-owned, and hospital-owned health care providers, competing primarily on service quality and personnel availability[113]. - A shortage of qualified clinicians could increase operating costs and adversely affect the company's ability to attract and retain personnel[158]. - Cybersecurity threats pose significant risks to the company's operations, and a breach could lead to substantial costs and reputational harm[171]. - The company relies on third-party vendors for critical information systems, and any security incidents involving these vendors could disrupt operations and impact financial performance[176]. - A recent cyber-attack on a subsidiary resulted in an estimated increase of approximately $60 million in accounts receivable due to delays in submitting non-Medicare claims[176]. Economic and Market Conditions - The ongoing inflationary environment has led to increased labor and healthcare costs, impacting the company's financial condition[189]. - Economic downturns and federal budget pressures may result in reduced payments and covered services under Medicare and Medicaid programs, adversely affecting the company's financial condition[154]. - The company is exposed to geopolitical tensions, such as the Russia-Ukraine conflict, which may disrupt global supply chains and financial markets[188]. Future Outlook - Future changes in Medicare reimbursement policies could materially affect the company's financial condition and results of operations[139]. - The home health and hospice industry is highly competitive, with few barriers to entry, which may limit the company's market share[165]. - The success of the high acuity care segment depends on entering into risk-based contracts with managed care health plans; failure to do so could adversely affect financial results[169]. - The implementation of value-based purchasing could lead to adjustments in Medicare payments based on performance against quality measures, potentially impacting revenue[153].

Amedisys (AMED) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.94 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.57%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.14 per share when it actually produced earnings of $1, delivering a surprise of -12.28%.Over the la ...

Exhibit 99.1 AMEDISYS REPORTS FOURTH QUARTER AND YEAR END 2024 FINANCIAL RESULTS * See pages 2 and 13 - 14 for the definition and reconciliations of non-GAAP financial measures to GAAP measures. The supplemental slides provided in connection with the fourth quarter and year end 2024 earnings release can be found on the Investor Relations page of our website. In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the ...

Core Viewpoint - Amedisys, Inc. reported its financial results for the fourth quarter and full year of 2024, highlighting significant changes in revenue, net income, and operational metrics amid a pending merger with UnitedHealth Group [1][2]. Financial Performance - Net service revenue for Q4 2024 increased by $27.3 million to $598.1 million compared to $570.8 million in Q4 2023 [4]. - For the full year 2024, net service revenue rose by $111.9 million to $2,348.3 million from $2,236.4 million in 2023 [4]. - The company reported a net loss attributable to Amedisys, Inc. of $20.4 million for Q4 2024, which included merger-related expenses of $17.4 million and a non-cash goodwill impairment charge of $48.4 million [4]. - In contrast, the net income attributable to Amedisys, Inc. for Q4 2023 was $19.3 million, which included merger-related expenses of $11.5 million [4]. - Adjusted EBITDA for Q4 2024 was $54.6 million, down from $56.7 million in Q4 2023 [4]. - For the full year 2024, adjusted net income attributable to Amedisys, Inc. was $142.7 million, compared to $140.6 million in 2023 [4]. Operational Metrics - The company experienced a decline in Medicare revenue by 4% in Q4 2024, while non-Medicare revenue increased by 19% [19]. - Total admissions for Q4 2024 rose by 8% to 109,686 compared to 101,809 in Q4 2023 [19]. - The average Medicare revenue per completed episode increased to $3,030 in Q4 2024 from $2,997 in Q4 2023 [19]. Balance Sheet Highlights - As of December 31, 2024, total assets were $2,138.7 million, up from $2,060.2 million in 2023 [14]. - Cash and cash equivalents increased significantly to $303.2 million from $126.5 million in 2023 [14]. - Total liabilities stood at $958.7 million, compared to $940.4 million in 2023 [14]. Segment Information - In the Home Health segment, net service revenue for Q4 2024 was $377.0 million, up from $358.9 million in Q4 2023 [19]. - The Hospice segment reported net service revenue of $212.9 million for Q4 2024, compared to $206.0 million in Q4 2023 [23]. - The High Acuity Care segment generated $8.1 million in net service revenue for Q4 2024, an increase from $5.9 million in Q4 2023 [26].

The market expects Amedisys (AMED) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, ...

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors. "Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be," said Richard Ashworth, President and Chief Executive Officer. "We are p ...

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company’s highest honors. “Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be,” said Richard Ashworth, President and Chief Executive Officer. “We are ...